Pharmacogenomics of adverse drug reactions: practical applications and perspectives

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA279,1200–1205 (1998).▪ Excellent meta-analysis of 39 prospective studies from US hospitals assessing the incidence of serious adverse drug reactions, which can be evaluated as the sixth leading cause of mortaility in the USA.
  Medline CASGoogle Scholar
• 2  Moore T, Cohen M, Furberg C: Serious adverse drug events reported to the food and drug administration, 1998–2005. Arch. Intern. Med.167,1752–1759 (2008).
  Google Scholar
• 3  Pirmohamed M, James S, Meakin S et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ329,15–19 (2004).▪ Excellent observational study including 18,820 patients admitted over 6 months in two large English hospitals. Provides prevalence of admissions due to adverse drug reactions and the incurred cost.
  MedlineGoogle Scholar
• 4  DiMasi J: Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther.69,297–307 (2001).
  Medline CASGoogle Scholar
• 5  Wysowski D, Swartz L: Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002. Arch. Intern. Med.165,1363–1369 (2005).
  MedlineGoogle Scholar
• 6  Meyer UA: Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet.5,669–675 (2004).
  Medline CASGoogle Scholar
• 7  Frueh F, Amur S, Mummaneni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy28,992–998 (2008).
  MedlineGoogle Scholar
• 8  Wilke R, Lin D, Roden D et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov.6,904–916 (2007).
  Medline CASGoogle Scholar
• 9  Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet361,865–872 (2003).▪▪ Review discussing the methodologic pitfalls of pharmacogenomic association studies leading to poor reproducibility of the results of numerous studies
  MedlineGoogle Scholar
• 10  Anderson J, Horne B, Stevens S et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation116,2563–2570 (2007).
  Medline CASGoogle Scholar
• 11  Behre H, Greb R, Mempel A et al.: Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet. Genomics15,451–456 (2005).
  Medline CASGoogle Scholar
• 12  Caraco Y, Blotnick S, Muszkat M: CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther.83,460–470 (2008).
  Medline CASGoogle Scholar
• 13  Furuta T, Shirai N, Kodaira M et al.: Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther.81,521–528 (2007).
  Medline CASGoogle Scholar
• 14  Hillman MA, Wilke RA, Yale SH et al.: A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res.3,137–145 (2005).
  Medline CASGoogle Scholar
• 15  Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358,568–579 (2008).▪▪ Largest randomized, controlled trial in pharmacogenomics demonstrating the usefulness of HLA-B*5701 screening to prevent hypersensitivity reactions to abacavir. Reports a 100% predictive positive value.
  MedlineGoogle Scholar
• 16  Quteineh L, Verstuyft C, Furlan V et al.: Influence of CYP3A5 genetic polymorphism on tacrolimus daily requirements, acute rejection and nephrotoxicity in renal graft recipients. Basic Clin. Pharmacol. Toxicol.103,546–552 (2008).
  Medline CASGoogle Scholar
• 17  Macphee I, Fredericks S, Tai T et al.: Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation74,1486–1489 (2002).
  Medline CASGoogle Scholar
• 18  Anglicheau D, Legendre C, Beaune P, Thervet E: Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics8,835–849 (2007).
  CASGoogle Scholar
• 19  Llerena A, Michel G, Jeannesson E et al.: Third Santorini conference pharmacogenomics workshop report: ‘Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?’ Clin. Chem. Lab. Med.45,843–850 (2007).
  MedlineGoogle Scholar
• 20  Owen R, Klein T, Altman R: The education potential of the pharmacogenetics and pharmacogenomics knowledge base (PharmGKB). Clin. Pharmacol. Ther.82,472–475 (2007).
  Medline CASGoogle Scholar
• 21  Patel K, Babyatsky M: Medical education: a key partner in realizing personalized medicine in gastroenterology. Gastroenterology134,656–661 (2008).
  MedlineGoogle Scholar
• 22  Shields A, Lerman C: Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Ther.83,635–639 (2008).
  Medline CASGoogle Scholar
• 23  Deverka P, McLeod H: Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin. Pharmacol. Ther.84,191–193 (2008).
  Medline CASGoogle Scholar
• 24  Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma M: Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics26,569–587 (2008).
  Medline CASGoogle Scholar
• 25  Criswell LA, Lum RF, Turner KN et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum.50,2750–2756 (2004).
  Medline CASGoogle Scholar
• 26  Ferrell P, McLeod H: Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics9,1543–1546 (2008).
  CASGoogle Scholar
• 27  Hung S, Chung W, Liou L et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA102,4134–4139 (2005).
  Medline CASGoogle Scholar
• 28  Gatanaga H, Honda H, Oka S: Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics9,207–214 (2008).▪▪ Review on the different HLA alleles predictive of drug response.
  CASGoogle Scholar
• 29  Young B, Squires K, Patel P et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS22,1673–1675 (2008).
  Medline CASGoogle Scholar
• 30  Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis.43,99–102 (2006).
  Medline CASGoogle Scholar
• 31  Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr.45,1–3 (2007).
  Medline CASGoogle Scholar
• 32  Schackman B, Scott C, Walensky R, Losina E, Reedberg K, Sax P: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS22,2025–2033 (2008).
  MedlineGoogle Scholar
• 33  Horton R, Wilming L, Rand V et al.: Gene map of the extended major histocompatibility complex. Nat. Rev. Genet.5,889–899 (2004).
  Medline CASGoogle Scholar
• 34  Ingelman -Sundberg M: Pharmacogenomic biomarkers for prediction of severe adverse dreug reactions. N. Engl. J. Med.358,637–639 (2008).
  MedlineGoogle Scholar
• 35  Klein R: Power analysis for genome-wide association studies. BMC Genet.8,58 (2007).
  MedlineGoogle Scholar
• 36  Li Q, Zheng G, Li Z, Yu KS: Efficient approximation of p-value of the maximum of correlated tests, with applications to genome-wide association studies. Ann. Hum. Genet.72,397–406 (2008).
  MedlineGoogle Scholar
• 37  Nelson M, Bacanu S-A, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J.9,23–33 (2008).▪▪ Excellent review on the methodological aspects of genome-wide association studies and study power, providing the major determinants of the number of patients to include.
  MedlineGoogle Scholar
• 38  Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359,789–799 (2008).▪ Genome-wide association study that clearly demonstrates that SLC01B1 is related to statin myopathy.
  Medline CASGoogle Scholar
• 39  Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics15,513–522 (2005).
  Medline CASGoogle Scholar
• 40  Neuvonen PJ, Backman JT, Niemi M: Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin. Pharmacokinet.47,463–474 (2008).
  Medline CASGoogle Scholar
• 41  Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics16,873–879 (2006).
  Medline CASGoogle Scholar
• 42  Wolfberg A: Genes on the Web – direct-to-consumer marketing of genetic testing. N. Engl. J. Med.345,543–545 (2006).
  Google Scholar
• 43  Mega J, Close S, Wiviott S et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360,354–362 (2009).
  Medline CASGoogle Scholar
• 44  Simon T, Verstuyft C, Mary-Krause M et al.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360,363–375 (2009).
  Medline CASGoogle Scholar
• 45  Mardis E: The impact of next-generation sequencing technology on genetics. Trends Genet.24,133–141 (2008).
  Medline CASGoogle Scholar
• 46  Chung W, Hung S, Hong H et al.: Medical genetics: a marker for Stevens–Johnson syndrome. Nature428,486 (2004).
  Medline CASGoogle Scholar
• 47  Donaldson P, Bhatnagar P, Graham J et al.: Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor. Hepatology48,396A–397A (2008).
  Google Scholar
• 48  Hoskins J, Goldberg R, Qu P, Ibrahim J, McLeod H: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl Cancer Inst.99,1290–1295 (2007).
  Medline CASGoogle Scholar
• 49  Côté J, Kirzin S, Kramar A et al.: UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. J. Clin. Oncol.13,3269–3275 (2007).
  CASGoogle Scholar
• 50  Martin A, Nolan D, James I et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS19,97–99 (2005).
  Medline CASGoogle Scholar
• 51  Littera R, Carcassi C, Masala A et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS20,1624–1626 (2006).
  Google Scholar
• 52  Quteineh L, Verstuyft C, Descot C et al.: Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb. Haemost.94,690–691 (2005).
  Medline CASGoogle Scholar
• 53  Lucena M, Andrade R, Martínez C et al.: Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology48,588–596 (2009).
  Google Scholar
• 54  Daly A, Aithal G, Leathart J, Swainsbury R, Dang T, Day C: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology132,272–281 (2007).
  Medline CASGoogle Scholar
• 55  Huang YS, Chern H, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology35,883–889 (2002).
  Medline CASGoogle Scholar
• 56  Possuelo L, Castelan J, de Brito T et al.: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol.64,673–681 (2008).
  Medline CASGoogle Scholar
• 57  Kindmark A, Jawaid A, Harbron C et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J.8,186–195 (2008).
  Medline CASGoogle Scholar
• 58  Simon T, Becquemont L, Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther.67,432–437 (2000).
  Medline CASGoogle Scholar
• 101  Tacrolimus in renal transplantation: individualization by pharmacogenetic www.clinicaltrials.gov/ct2/show/NCT00552201
  Google Scholar
• 102  Registry of federally and privately supported clinical trials conducted in the USA and around the world www.clinicaltrials.gov
  Google Scholar
• 103  International warfarin pharmacogenetics consortium. Provides an algorithm which predicts the warferin daily dose requirement based on pharmacogenetic and clinical factors www.warfarindosing.org
  Google Scholar
• 104  US FDA Center of Drug Evaluation and Research where the drug product characteristics, including pharmacogenomics labels, are updated www.fda.gov/cder/genomics/
  Google Scholar
• 105  European Medicines Agency www.emea.europa.eu/
  Google Scholar